These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

751 related articles for article (PubMed ID: 34375715)

  • 21. Discovery of Novel Spike Inhibitors against SARS-CoV-2 Infection.
    Tai LT; Yeh CY; Chang YJ; Liu JF; Hsu KC; Cheng JC; Lu CH
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
    Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
    EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
    Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
    Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2.
    Higuchi Y; Suzuki T; Arimori T; Ikemura N; Mihara E; Kirita Y; Ohgitani E; Mazda O; Motooka D; Nakamura S; Sakai Y; Itoh Y; Sugihara F; Matsuura Y; Matoba S; Okamoto T; Takagi J; Hoshino A
    Nat Commun; 2021 Jun; 12(1):3802. PubMed ID: 34155214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies.
    Rattanapisit K; Bulaon CJI; Khorattanakulchai N; Shanmugaraj B; Wangkanont K; Phoolcharoen W
    PLoS One; 2021; 16(8):e0253574. PubMed ID: 34379620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advancements in the Development of Anti-SARS-CoV-2 Therapeutics.
    Huang J; Ma Q; Su Z; Cheng X
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39409149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2.
    Jafary F; Jafari S; Ganjalikhany MR
    Sci Rep; 2021 Mar; 11(1):6927. PubMed ID: 33767306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of a Potential Allosteric Site in the SARS-CoV-2 Spike Protein and Targeting Allosteric Inhibitor to Stabilize the RBD Down State using a Computational Approach.
    Li T; Yan Z; Zhou W; Liu Q; Liu J; Hua H
    Curr Comput Aided Drug Des; 2024; 20(6):784-797. PubMed ID: 37493168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a nano-luciferase based assay to measure the binding of SARS-CoV-2 spike receptor binding domain to ACE-2.
    Lima MA; Skidmore M; Khanim F; Richardson A
    Biochem Biophys Res Commun; 2021 Jan; 534():485-490. PubMed ID: 33239166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.
    Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B
    J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19.
    Ahmad I; Pawara R; Surana S; Patel H
    Top Curr Chem (Cham); 2021 Oct; 379(6):40. PubMed ID: 34623536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Lapaillerie D; Charlier C; Fernandes HS; Sousa SF; Lesbats P; Weigel P; Favereaux A; Guyonnet-Duperat V; Parissi V
    Viruses; 2021 Feb; 13(3):. PubMed ID: 33669132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein.
    Svilenov HL; Sacherl J; Reiter A; Wolff LS; Cheng CC; Stern M; Grass V; Feuerherd M; Wachs FP; Simonavicius N; Pippig S; Wolschin F; Keppler OT; Buchner J; Brockmeyer C; Protzer U
    Antiviral Res; 2021 Dec; 196():105197. PubMed ID: 34774603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computational analysis of spike protein of SARS-CoV-2 (Omicron variant) for development of peptide-based therapeutics and diagnostics.
    Pritam M; Dutta S; Medicherla KM; Kumar R; Singh SP
    J Biomol Struct Dyn; 2024 Sep; 42(14):7321-7339. PubMed ID: 37498146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.
    Larue RC; Xing E; Kenney AD; Zhang Y; Tuazon JA; Li J; Yount JS; Li PK; Sharma A
    Bioconjug Chem; 2021 Jan; 32(1):215-223. PubMed ID: 33356169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computational design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 S protein.
    Pei P; Qin H; Chen J; Wang F; He C; He S; Hong B; Liu K; Qiao R; Fan H; Tong Y; Chen L; Luo SZ
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34180984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor.
    Lata S; Akif M
    J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface.
    Villoutreix BO; Calvez V; Marcelin AG; Khatib AM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.